ClinicalTrials.gg

Program

Dexmedetomidine

Also written as “BXCL501”, “Intranasal Dexmedetomidine” and “Dexmedetomidine hydrochloride”.

Its studies are mostly in Psychomotor Agitation · Delirium · Schizophrenia · Bipolar Disorder · Dementia, led by 8 companies.

Furthest: phase 4, since Aug 31, 200545 company-led studies, 3 open or runningNext primary completion: Jul 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer160 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
BioXcel Therapeutics131 open or runningphase 4since Sep 11, 2023Jul 3, 2019Jul 31, 2027phase 1 · NCT05025605
Orion Corporation, Orion Pharma50 open or runningphase 4since Nov 9, 2018Sep 23, 2005none ahead
Jiangsu HengRui Medicine40 open or runningphase 3since May 6, 2020Aug 23, 2017none ahead
Baudax Bio20 open or runningphase 2since Jun 17, 2014Jun 17, 2014none ahead
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology21 open or runningno phasesince Jul 11, 2023Jul 11, 2023none ahead
Egymedicalpedia21 open or runningearly phase 1since Apr 8, 2023Apr 8, 2023none ahead
Teikoku Pharma USA10 open or runningphase 1since Sep 7, 2026Sep 7, 2026none ahead

Also a collaborator on its studies: cognitive-research-corporation, propharma-group and maruishi-pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 30 studies since Aug 31, 2005.

  1. Jul 1, 2020Phase 2 study in Opioid-Related DisordersBioXcel Therapeutics · NCT04470050 · 225 enrolled · United States
  2. Mar 31, 2021Phase 2 study in Psychomotor AgitationBioXcel Therapeutics · NCT05313386 · United States
  3. Aug 24, 2021Phase 1 study in SchizophreniaBioXcel Therapeutics · NCT05025605 · 140 planned · United States
  4. Oct 20, 2021Phase 3 study in Preoperative Sedation of ChildrenJiangsu HengRui Medicine · NCT05111431 · 159 enrolled · China
  5. Feb 28, 2022Phase 2 study in Psychomotor AgitationBioXcel Therapeutics · NCT05276830 · 5 enrolled · United States
  6. Feb 28, 2022Phase 3 study in Psychomotor AgitationBioXcel Therapeutics · NCT05271552 · 151 enrolled · United States
  7. Dec 12, 20222 phase 3 studies in Psychomotor AgitationBioXcel Therapeutics · NCT05658510, NCT05665088
  8. Apr 8, 2023Egymedicalpedia's first study: early phase 1 study in Endoscopic Sinus SurgeryNew to EgymedicalpediaEgymedicalpedia · NCT05829148 · 120 enrolled · Egypt
  9. Jul 11, 2023Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology's first study: no phase study in Emergence DeliriumNew to Boston Intelligent Medical Research Center, Shenzhen United Scheme TechnologyBoston Intelligent Medical Research Center, Shenzhen United Scheme Technology · NCT05952050 · 120 planned · China
  10. Sep 11, 2023Phase 4 study in Bipolar DisorderBioXcel Therapeutics · NCT06041646 · 29 enrolled · United States
  11. Apr 22, 2024No phase study in Delirium in Old AgeBoston Intelligent Medical Research Center, Shenzhen United Scheme Technology · NCT06382961 · 287 enrolled · China
  12. Jun 9, 2024No phase study in Valvular Cardiac SurgeriesEgymedicalpedia · NCT06464263 · 60 planned · Egypt
  13. Jul 7, 2025Phase 2 study in Bipolar DisorderBioXcel Therapeutics · NCT07116694 · 33 enrolled · United States
  14. Sep 7, 2026Teikoku Pharma USA's first study: phase 1 study in Healthy SubjectsNew to Teikoku Pharma USATeikoku Pharma USA · NCT07818330 · 8 enrolled · Australia

Ahead

  1. Jul 31, 2027Primary completion: phase 1 study in SchizophreniaBioXcel Therapeutics · NCT05025605

TargetBeta

“Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brimonidineruleAbbViephase 454
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
Clonidinerulepharmafinaphase 45
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 45 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07818330Healthy Subjects · Australia1TerminatedTeikoku Pharma USAOct 30, 20268
NCT07116694Bipolar Disorder · United States2CompletedBioXcel TherapeuticsOct 7, 202533
NCT06464263Valvular Cardiac Surgeries · Egypt–RecruitingEgymedicalpediaFeb 1, 202660
NCT06382961Delirium in Old Age · China–CompletedBoston Intelligent Medical Research Center, Shenzhen United Scheme TechnologyMar 6, 2024287
NCT06041646Bipolar Disorder · United States4CompletedBioXcel TherapeuticsApr 29, 202429
NCT05952050Emergence Delirium · China–RecruitingBoston Intelligent Medical Research Center, Shenzhen United Scheme TechnologyAug 1, 2023120
NCT05829148Endoscopic Sinus Surgery · EgyptEarly 1UNKNOWNEgymedicalpediaNov 1, 2024120
NCT05665088Psychomotor Agitation · United States3TerminatedBioXcel TherapeuticsSep 11, 202313
NCT05658510Psychomotor Agitation · United States3CompletedBioXcel TherapeuticsAug 15, 2025452
NCT05276830Psychomotor Agitation · United States2TerminatedBioXcel TherapeuticsApr 1, 20225
NCT05271552Psychomotor Agitation · United States3CompletedBioXcel TherapeuticsApr 21, 2023151
NCT05111431Preoperative Sedation of Children · China3CompletedJiangsu HengRui MedicineMay 20, 2022159
NCT05025605Schizophrenia · United States1RecruitingBioXcel TherapeuticsJul 31, 2027140
NCT05313386Psychomotor Agitation · United States2WithdrawnBioXcel TherapeuticsFeb 21, 20220
NCT04470050Opioid-Related Disorders · United States2CompletedBioXcel TherapeuticsFeb 18, 2021225
NCT04383418Preoperative Sedation · China3CompletedJiangsu HengRui MedicineJun 2, 2021309
NCT04276883Psychomotor Agitation · United States3CompletedBioXcel TherapeuticsMay 21, 2020380
NCT04268303Psychomotor Agitation · United States3CompletedBioXcel TherapeuticsMay 6, 2020380
NCT04251910Psychomotor Agitation · United States2CompletedBioXcel TherapeuticsJan 24, 2022100
NCT04237792MRI Sedation · United States, Japan4CompletedPfizerNov 2, 2021128
NCT04200235Preoperative Sedation · China1CompletedJiangsu HengRui MedicineAug 6, 202048
NCT04010305Psychomotor Agitation · United States1CompletedBioXcel TherapeuticsJul 31, 2019135
NCT03813277ICU Sedation · Russia4CompletedOrion Corporation, Orion PharmaMay 21, 201860
NCT03293277Sedation · China1UNKNOWNJiangsu HengRui MedicineJul 201848
NCT02757625ICU Sedation · Japan3CompletedPfizerMay 24, 201763
NCT02284243Pain, Postoperative · United States2CompletedBaudax BioJun 2015168
NCT02169336Pain, Postoperative · United States2TerminatedBaudax BioSep 201495
NCT01519167Ultrasound · United States, Puerto Rico4CompletedPfizerJan 201491
NCT01508455Anesthesia · United States3CompletedPfizerMay 20126
NCT01438957Sedation · Japan3CompletedPfizerNov 18, 2011119
NCT01378988Pain · United States2CompletedPfizerAug 20115
NCT01159262Sedation · United States, Guatemala3CompletedPfizerAug 201136
NCT00875550Sedation · United States, Canada3CompletedPfizerJan 2011175
NCT00747721Pharmacokinetics · Finland1CompletedOrion Corporation, Orion PharmaJan 200913
NCT00652028Intubated and Mechanically Ventilated Pediatric Subjects · United States, Guatemala2CompletedPfizerApr 201069
NCT00526760Sedation · Japan3CompletedPfizerJun 200880
NCT00481312Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Estonia, Finland and more3CompletedOrion Corporation, Orion PharmaAug 2009501
NCT00479661Continuous Sedation in Initially Sedated Adults in ICU · Belgium, Finland, Germany and more3CompletedOrion Corporation, Orion PharmaMar 2010500
NCT00464763Delirium · United States3WithdrawnPfizer0
NCT00460473Delirium · United States3TerminatedPfizerNov 200752
NCT00398827Anesthesia · United States3CompletedPfizer326
NCT00383890Awake Fiberoptic Intubation · United States3CompletedPfizerJan 2007124
NCT00318955Conscious Sedation · Japan4CompletedPfizerAug 200685
NCT00226785Conscious Sedation · Finland, Switzerland3TerminatedOrion Corporation, Orion Pharma900
NCT00216190Mechanically Ventilated and Intubated Subjects · United States, Argentina, Australia and more4CompletedPfizer420

How it is read

Names in the registry

  • “Dexmedetomidine”, 20 entries
  • “BXCL501”, 6 entries
  • “Intranasal Dexmedetomidine”, 3 entries
  • “Dexmedetomidine hydrochloride”, 2 entries
  • “Dexmedetomidine HCL Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.